An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies
Saved in:
Main Authors: | Alison Findlay, Craig Turner, Heidi Schilter, Mandar Deodhar, Wenbin Zhou, Lara Perryman, Jonathan Foot, Amna Zahoor, Yimin Yao, Ross Hamilton, Mary Brock, Christina Raso, Jessica Stolp, Marie Galati, Dieter Hamprecht, Brett Charlton, Wolfgang Jarolimek |
---|---|
Format: | article |
Language: | EN |
Published: |
Wiley
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/c99b1b5618214a2193bedd33dab46b7d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Facilitation of molecular motion to develop turn-on photoacoustic bioprobe for detecting nitric oxide in encephalitis
by: Ji Qi, et al.
Published: (2021) -
LOXL2 attenuates osteoarthritis through inactivating Integrin/FAK signaling
by: Caixia Zhang, et al.
Published: (2021) -
Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment
by: Jin Yang, et al.
Published: (2016) -
Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis Partly by Inhibiting the Expression of LOX and LOXL-2
by: Xiang Tong, et al.
Published: (2021) -
The lncRNA GATA6-AS epigenetically regulates endothelial gene expression via interaction with LOXL2
by: Philipp Neumann, et al.
Published: (2018)